Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triamterene

FDA-approved product (capsule, oral), marketed as Dyrenium, Triamterene.

Registered studies
8
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Triamterene
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Hyperaldosteronism
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other potassium-sparing agents
FDA pharmacologic class
Potassium-sparing Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triamterene in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triamterene with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Meniere's Disease With Migraine Medications

    NCT05582837 · start 2022-08-01

    Registered record
    Registry ID
    NCT05582837
    Conditions
    Ménière
    Interventions
    nortriptyline + topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-08-01
    Completion
    2027-12-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMénière
    Interventionnortriptyline + topiramate
    PhasePhase 4
    Registry statusRecruiting

  • Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene

    NCT05125237 · start 2021-10-01

    Registered record
    Registry ID
    NCT05125237
    Conditions
    Hypertension
    Interventions
    Amiloride; Triamterene
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-01
    Completion
    2023-12-31
    Enrolment
    155,963

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmiloride; Triamterene
    PhaseNot recorded
    Registry statusCompleted

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease

    NCT01918488 · start 2013-10

    Registered record
    Registry ID
    NCT01918488
    Conditions
    Diabetic Nephropathies; Hypertension
    Interventions
    Standardized salt diet; Amiloride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-10
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathies; Hypertension
    InterventionStandardized salt diet; Amiloride
    PhaseNot applicable
    Registry statusUnknown

  • A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

    NCT02522650 · start 2013-07

    Registered record
    Registry ID
    NCT02522650
    Conditions
    Proteinuria
    Interventions
    Amiloride; Triamterene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-07
    Completion
    2021-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProteinuria
    InterventionAmiloride; Triamterene
    PhasePhase 4
    Registry statusUnknown

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Action to Control Cardiovascular Risk in Diabetes (ACCORD)

    NCT00000620 · start 1999-09

    Registered record
    Registry ID
    NCT00000620
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease
    Interventions
    Anti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-09
    Completion
    2012-12
    Enrolment
    10,251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension +3 more
    InterventionAnti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    PhasePhase 3
    Registry statusCompleted

  • Diuretics, Hypertension, and Arrhythmias Clinical Trial

    NCT00000525 · start 1986-07

    Registered record
    Registry ID
    NCT00000525
    Conditions
    Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Arrest; Heart Diseases; Hypertension
    Interventions
    hydrochlorothiazide; diet, potassium supplementation; diet, magnesium supplementation; triamterene; chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1986-07
    Completion
    Not recorded
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Death, Sudden, Cardiac; Heart Arrest; Heart Diseases +1 more
    Interventionhydrochlorothiazide; diet, potassium supplementation; diet, magnesium supplementation; triamterene +1 more
    PhasePhase 3
    Registry statusCompleted